|
As BIO-Europe 2024 kicks off in Stockholm from November 4 to 6, the city continues to solidify its status as a leading life science hub. Photo: SBR/Johannes Frandsen
A unique Swedish law, which grants researchers ownership of their innovations, has fostered a dynamic start-up ecosystem in Stockholm-Uppsala, with the number of life science companies growing by over 50% in a decade. As BIO-Europe 2024 kicks off in Stockholm from November 4 to 6, the city continues to solidify its status as a leading life science hub in Europe and across the globe.
BIO-Europe is one of the world’s premier life science investment events, and this year it is expected to attract more than 5,500 decision-makers to Stockholm who will engage in over 30,000 one-to-one meetings.“We are proud and excited to host BIO-Europe 2024! In addition to its scientific strengths, Stockholm stands as a beacon of sustainability and innovation, making it the perfect host city for the 30th anniversary of BIO-Europe. The region’s pioneering work in precision medicine, artificial intelligence, and health data is reshaping the future of healthcare, particularly in preventive care and technology-driven therapies,” says Ylva Hultman, Head of Life Science at Stockholm Business Region.
A key factor behind the region’s success is Sweden’s unique “Teachers’ Exemption” law. This policy, which exempts universities and employers from claiming rights to employees’ patentable inventions, empowers academic researchers to commercialize their innovations. Professor Mathias Uhlén, Professor at the KTH Royal Institute of Technology and the Karolinska Institutet in Stockholm, and a serial entrepreneur, who has launched over 20 life science companies focusing on Alzheimer’s disease and cancer, will be one of the keynote speakers at the event.
A robust regulatory framework and critical institutions like the European Centre for Disease Prevention and Control (ECDC), the Swedish Medicines Agency, and the Centre for Health Crises further support Stockholm’s leadership in life sciences. Additionally, the International Vaccine Institute’s (IVI) European Regional Office and UNICEF’s Innovation Office bolster the region’s international standing as a leader in healthcare innovation and global health solutions.
Celebrating its 30th anniversary, BIO-Europe 2024 is set to be the largest edition yet, offering an unparalleled opportunity to connect with global leaders and explore groundbreaking innovations shaping the future of medicine.
Read more: https://www.stockholmbusinessregion.com/insights/life-science/
|
